Aktuellt
SENASTE
Redeye endorses the news that the company’s disease awareness activities have resulted in an additional 50 patients being diagnosed with MCT8 deficiency – i.e., patients previously unknown by the company. As a result of the increased number of patients eligible for the early access program, Egetis has partnered with a specialty pharmacy company (AnovoRX) to assist with broadening the program. We think that the increased number of diagnosed patients bode well for the launch of Emcitate, which we expect in early 2025, and hope to learn more soon about the company's disease awareness activities (potentially in relation to the investor day next week).
LÄS MER
